Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2013

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
HemochromatosisMyelodysplastic Syndromes
Interventions
DRUG

Deferasirox

Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months

OTHER

Venesection

Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.

DRUG

Deferasirox

Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.

Trial Locations (1)

5021

Haukeland University Hospital, Clinical Trial Unit, Bergen

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Haukeland University Hospital

OTHER

NCT01892644 - Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter